Combined Checkpoint Inhibition Amplifies Post-Infarction Injury via T Cell-Mediated Macrophage Activation
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
This study aimed to investigate whether combined PD-1/CTLA-4 immune checkpoint inhibition predisposes the heart to a hyperinflammatory state, thereby exacerbating cardiac injury following acute myocardial infarction (MI), a critical unresolved question in cardio-oncology.
Methods
Myocardial infarction was induced in Pd1 −/− Ctla4 +/− mice, a genetic model mimicking combined checkpoint inhibition. Key mechanistic insights were gained through in vivo depletion of CD8 + T cells (using anti-CD8a antibody) and pharmacological inhibition of the JAK-STAT1 pathway (using Tofacitinib). Cardiac function, structural injury, and immune responses were comprehensively assessed via echocardiography, flow cytometry, immunofluorescence, and molecular analyses.
Results
Compared to wild-type controls, Pd1 −/− Ctla4 +/− mice exhibited significantly increased post-MI mortality, worse cardiac function, and larger infarct size. Mechanistically, the aggravated injury was driven by an amplified infiltration of activated, IFN-γ-producing CD8 + T cells, which activated the JAK-STAT1 pathway in macrophages, polarizing them towards a pro-inflammatory state. Depleting CD8 + T cells or inhibiting the JAK-STAT1 pathway effectively attenuated macrophage-driven inflammation and improved all aspects of post-MI injury.
Conclusions
Combined PD-1/CTLA-4 blockade exacerbates post-infarction cardiac injury by promoting CD8 + T cell-mediated activation of macrophages via the JAK-STAT1 axis. This work elucidates MI as a context-dependent immune-related adverse event in ICI therapy and identifies CD8 + T cells and the JAK-STAT1 pathway as promising therapeutic targets for cardioprotection in these patients.
RESEARCH PERSPECTIVE
What Is New?
-
This study identifies acute myocardial infarction (MI) as a potential, context-dependent immune-related adverse event in the setting of combined PD-1/CTLA-4 checkpoint inhibition, shifting the paradigm beyond the classic focus on myocarditis.
-
It elucidates a novel pathogenic axis where combined checkpoint deficiency exacerbates post-MI injury specifically through CD8 + T cell-derived IFN-γ, which activates macrophages via the JAK-STAT1 pathway.
What Question Should Be Addressed Next?
-
Future studies should employ anti-PD-1/CTLA-4 monoclonal antibodies in wild-type or humanized mouse models to validate findings and better recapitulate the pharmacokinetics of clinical ICI therapy, strengthening translational relevance.
-
The long-term consequences of this primed inflammatory state on chronic cardiac remodeling, heart failure development, and the potential interplay with atherosclerosis warrant further investigation.
